https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-07-21 / J Immunother Cancer 2015;3:32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-07-21 / J Immunother Cancer 2015;3:322015-07-21 00:00:002019-02-15 08:47:50Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-26 / Mol. Ther. 2015 Oct;23(10):1630-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-26 / Mol. Ther. 2015 Oct;23(10):1630-402015-06-26 00:00:002019-02-15 09:22:35Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-18 / Crit. Rev. Oncol. Hematol. 2015 Nov;96(2):339-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-18 / Crit. Rev. Oncol. Hematol. 2015 Nov;96(2):339-542015-06-18 00:00:002019-02-15 08:51:18Vaccination of multiple myeloma: Current strategies and future prospects
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-17 / J Clin Oncol 33, 2015 (suppl; abstr e13030)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-17 / J Clin Oncol 33, 2015 (suppl; abstr e13030)2015-06-17 12:08:122019-07-17 12:08:33Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-17 / Front Oncol 2015;5:98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-17 / Front Oncol 2015;5:982015-06-17 00:00:002021-11-15 13:27:21Brain Tumor Immunotherapy: What have We Learned so Far?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-322015-06-13 00:00:002021-11-15 13:28:49Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-11 / Viruses 2015 Jun;7(6):2980-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-11 / Viruses 2015 Jun;7(6):2980-982015-06-11 00:00:002015-06-11 00:00:00Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-02 / Front Immunol 2015;6:271
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-02 / Front Immunol 2015;6:2712015-06-02 00:00:002015-06-02 00:00:00Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr 2036)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr 2036)2015-06-01 12:02:252019-07-17 12:02:49Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr TPS9082)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr TPS9082)2015-06-01 11:35:202019-07-17 11:35:43Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (INTUS trial).
